Cerus Corp. (NASDAQ:CERS) shares traded up 2.3% during mid-day trading on Friday . The company traded as high as $6.85 and last traded at $6.75, with a volume of 1,637,088 shares trading hands. The stock had previously closed at $6.60.

A number of research analysts have issued reports on the stock. Robert W. Baird set a $10.00 target price on shares of Cerus Corp. and gave the company a “buy” rating in a report on Saturday, August 6th. FBR & Co restated a “buy” rating on shares of Cerus Corp. in a report on Monday, May 23rd. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Cerus Corp. in a report on Monday, June 20th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 target price on shares of Cerus Corp. in a report on Thursday, July 7th. Finally, Zacks Investment Research lowered shares of Cerus Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.10.

The firm has a 50-day moving average of $6.75 and a 200 day moving average of $6.06. The company’s market cap is $693.29 million.

Cerus Corp. (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. The firm earned $9.25 million during the quarter, compared to the consensus estimate of $8.88 million. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) earnings per share. Equities research analysts anticipate that Cerus Corp. will post ($0.68) earnings per share for the current year.

In other news, CFO Kevin Dennis Green sold 17,150 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total transaction of $116,620.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.